|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
11084807 |
| 005 |
20170630050406.8 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
140502s2014 sz a o 010 0 eng d |
| 003 |
ICU |
| 040 |
|
|
|a GW5XE
|b eng
|e rda
|e pn
|c GW5XE
|d N$T
|d YDXCP
|d COO
|d BTCTA
|d OCLCO
|d VAM
|d OCLCF
|d IDEBK
|d CDX
|d BEDGE
|d OCLCQ
|d Z5A
|
| 020 |
|
|
|a 9783319051048
|q (electronic bk.)
|
| 020 |
|
|
|a 3319051040
|q (electronic bk.)
|
| 020 |
|
|
|a 3319051032
|q (print)
|
| 020 |
|
|
|a 9783319051031
|q (print)
|
| 020 |
|
|
|z 9783319051031
|
| 024 |
7 |
|
|a 10.1007/978-3-319-05104-8
|2 doi
|
| 035 |
|
|
|a (OCoLC)878948250
|
| 050 |
|
4 |
|a RC271.I45
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 049 |
|
|
|a MAIN
|
| 245 |
0 |
0 |
|a Cancer immunotherapy meets oncology :
|b in honor of Christoph Huber /
|c Cedrik Michael Britten, Sebastian Kreiter, Mustafa Diken, Hans-Georg Rammensee, editors.
|
| 264 |
|
1 |
|a Cham :
|b Springer,
|c 2014.
|
| 300 |
|
|
|a 1 online resource (ix, 248 pages) :
|b illustrations (some color)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/c
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/cr
|
| 505 |
0 |
|
|a From Basic Immunology to New Therapies for Cancer Patients -- How T Cells Single Out Tumor Cells: "And That Has Made All the Difference" -- Effects of Regulatory T Cell-Dendritic Cell Interactions on Adaptive Immune Responses -- Evolution of the Regulatory Landscape for Immunomodulatory Compounds and Personalized Therapeutic Cancer Vaccines -- Immunoguiding, the Final Frontier in the Immunotherapy of Cancer -- Developing Cancer Immunotherapies as Drugs: Setting the Stage Through Methodological Progress -- Immunotherapies -- Reflections on Cancer Vaccines -- Dendritic Cell-Based Cancer Vaccines -- mRNA Vaccination and Personalized Cancer Therapy -- Antibody Therapy in Oncology -- Bispecific Antibodies for the Treatment of Cancer: The Challenges of Translation -- The ABCs of T Cell Receptor Gene Therapy -- The Express Drivers: Chimeric Antigen Receptor-Redirected T Cells Make It to the Clinic -- Cancer Entities -- Immunotherapy of Malignant Melanoma -- Prostate Cancer Vaccines Generated with the Disruptive RNActive® Technology Follow the Path Paved by Sipuleucel-T and Prostvac-VF -- Recent Developments in the Active Immunotherapy of Renal Cell Cancer -- Current Status of Immunotherapy in Gastroesophageal Cancer -- Non-small Cell Lung Cancer, NSCLC -- Towards More Specificity and Effectivity in the Antileukemia Immune Response -- Biomarkers -- Molecular and Metabolic Cues of the Key-Lock Paradigm Dictating Immunogenic Cell Death -- Pathogenesis of Minimal Residual Disease: CTCs as Novel Biomarkers in Cancer Disease -- Genomics Meets Cancer Immunotherapy -- Oncolytic Viruses -- Final Words.
|
| 520 |
|
|
|a This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing. Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (SpringerLink, viewed May 2, 2014).
|
| 650 |
|
0 |
|a Cancer
|x Immunotherapy.
|0 http://id.loc.gov/authorities/subjects/sh87002642
|
| 650 |
1 |
4 |
|a Medicine & Public Health.
|
| 650 |
2 |
4 |
|a Oncology.
|
| 650 |
2 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Immunology.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Médecine.
|2 eclas
|
| 650 |
|
7 |
|a Cancer
|x Immunotherapy.
|2 fast
|0 (OCoLC)fst00845386
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Britten, Cedrik Michael,
|e editor.
|0 http://id.loc.gov/authorities/names/n2014189291
|1 http://viaf.org/viaf/311463502
|
| 700 |
1 |
|
|a Huber, Christoph,
|d 1970-
|e honoree.
|0 http://id.loc.gov/authorities/names/n2009182883
|1 http://viaf.org/viaf/102542950
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319051031
|
| 856 |
4 |
0 |
|u http://link.springer.com/10.1007/978-3-319-05104-8
|y SpringerLink
|
| 903 |
|
|
|a HeVa
|
| 929 |
|
|
|a eresource
|
| 999 |
f |
f |
|i 96370b71-dde9-57a9-9660-5ed1c172d2c5
|s 5329befa-3824-59f1-8f8a-ce3b3d0af923
|
| 928 |
|
|
|t Library of Congress classification
|a RC271.I45
|l Online
|c UC-FullText
|u http://link.springer.com/10.1007/978-3-319-05104-8
|z SpringerLink
|g ebooks
|i 9895045
|
